Company Overview and News
The June MLP Monthly Report can be found here offering insights on MLP industry news, the asset class’s performance, yields, valuations, and fundamental drivers.
SNSR MLPA AND LIT CVI BFIT KMI.WS GXG SIL KRMA GXF EPD CHII EV ACTX CHIE GOEX KMI.PRA KMI FINX CHIX KMR CVB SRET BOTZ CATH GURX GURI ALUM MILN CJHIQ URA BHI LNGR COPX CVRR QQQC KRP GURU KMRFZ
The following slide deck was published by Enterprise Products Partners L.P in conjunction with this event.
NEW YORK, June 20 (Reuters) - Seaway Crude Pipeline Company LLC, a joint venture between Enterprise Products Partners LP and Enbridge Inc, plans to load its first supertanker this month at its Texas City marine terminal:
ENBBF ENB EBBNF ENB EPD
This is just a quick note to our members regarding ClearBridge's proposal to merge ClearBridge American Energy MLP Fund Inc. (CBA) into ClearBridge Energy MLP Opportunity Fund Inc. (EMO), subject to approval by the stockholders of each fund.
ETP.PRC CBA ETP EMO EPD
Volatility is not the investor’s friend. Some will immediately take issue with this – volatility caused by falling prices can mean opportunity, and volatile rising prices are surely welcome. While true, investments that gyrate cause investor stress which often leads to poorly timed sell decisions. Although a company’s long-term profitability should be more important, the downside of liquid equity markets is that they offer a constant evaluation of your decisions.
KNOT Offshore Partners LP. (KNOP) owns and operates shipping vessels on long term charter contracts. KNOP offers a 9.7% yield and is structured to offer a 1099 at tax time, no K1 here - removing that additional stress. KNOP's high yielding status is here to stay for the midterm time frame.
What happens in the Permian Basin of West Texas and New Mexico reverberates through oil markets around the world - even all the way to the region's namesake, Perm, Russia. The new IHS Markit outlook for the Permian to 2023 projects crude oil production could reach 5.4 million barrels per day (MMb/d) in 2023 - up 2.9 MMb/d from 2017. This increment of growth is higher than the current entire output of Kuwait.
Chesapeake drilled and completed its first 15,000-foot lateral well which was placed into production on May 1st, 2018.
LNGLF APC CKRGZ XOM CHKVP TWX ENB EPD TWC CHKDH CHKVZ CHKDG CHKWZ ENB CHKDJ BP CHKDP T LNGLY CHK CHK.WI CHK.PRD AEUA LNG
Investing in real assets such as Real Estate Securities, Infrastructure Securities, and Natural Resources Securities offers a route to have a consistent revenue stream. The downside is that most individual investors do not have the capital available to purchase a mortgage-backed security outright. Brookfield Real Assets Income Fund Inc. (RA) provides a perfect opportunity to get into this asset class.
ETP.PRC HTR.RT ETP HTR O.PRF BOI O OPRF HHY EPD RA
Enterprise Products Partners (EPD) is a master limited partnership (‘MLP’) with a focus on natural gas and natural gas liquids. They have earned a reputation for being a blue chip MLP due to their history of consistent and generous distribution increases in addition to a strong balance sheet. Shares trade at a 5.8% yield in spite of a recent run up in price. Still, future growth is almost certain to be nothing like the past - what does this mean for their distribution? I analyze the key metric for EPD and give my verdict on shares.
BHI EPD MMP
UNITED STATES EPD
2018-06-18 - Asif
Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...
2018-06-11 - Asif
Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...
2018-06-11 - Asif
Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...
as of ET